TBX1 and neoplasm: As shown in Figure 2A, treatment with either dose of 223Ra increased the sensitivity of the breast, prostate, and lung carcinoma cell lines to CTL-mediated lysis targeting the CEA, MUC-1, and brachyury tumor antigens.